The Methodist Hospital Research Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Multi-scale Modeling of Breast Conserving Therapy

Conditions: Breast Cancer

First Posted Date: 2014-12-08

Last Posted Date: 2018-10-10

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 15

Registration Number: NCT02310711

Locations: 🇺🇸
Houston Methodist Hopsital, Houston, Texas, United States

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

Not Applicable

Completed

Conditions: End Stage Renal Disease

Interventions: Other: Patient-Guided
Other: Educator-Guided

First Posted Date: 2014-10-20

Last Posted Date: 2023-12-28

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 558

Registration Number: NCT02268682

Locations: 🇺🇸
UCLA Transplant Research and Education Center, Los Angeles, California, United States

Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant

Not Applicable

Completed

Conditions: End Stage Renal Disease

Interventions: Behavioral: Expert System Coaching

First Posted Date: 2014-07-03

Last Posted Date: 2023-12-28

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 815

Registration Number: NCT02181114

Locations: 🇺🇸
University of Rhode Island, Kingston, Rhode Island, United States
🇺🇸
UCLA Division of Nephrology, Los Angeles, California, United States

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

Phase 1

Terminated

Conditions: Glioma
Glioblastoma
Glioblastoma Multiforme

Interventions: Drug: FDOPA PET

First Posted Date: 2014-06-27

Last Posted Date: 2018-08-17

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 31

Registration Number: NCT02176720

Locations: 🇺🇸
Houston Methodist Research Institute PET Center, Houston, Texas, United States

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

Phase 1

Terminated

Conditions: Neoplasms by Site
Neoplasms
Lung Diseases
Thoracic Neoplasms
Lung Neoplasms

Interventions: Device: MIMIG System
Drug: Indocyanine Green (ICG)

First Posted Date: 2014-04-11

Last Posted Date: 2021-09-17

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 7

Registration Number: NCT02111824

Locations: 🇺🇸
MD Anderson Cancer Center Interventional Radiology Dept., Houston, Texas, United States

Single Dose rATG for Renal Allograft Rejection

Phase 4

Conditions: Acute (Cellular) Renal Allograft Rejection

Interventions: Drug: rATG

First Posted Date: 2014-04-03

Last Posted Date: 2020-09-03

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 30

Registration Number: NCT02102854

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: T-DM1
Drug: Trastuzumab
Drug: Lapatinib
Drug: Paclitaxel
Drug: Abraxane
Drug: Pertuzumab

First Posted Date: 2014-02-27

Last Posted Date: 2021-09-22

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 32

Registration Number: NCT02073487

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸
Houston Methodist Hospital Willowbrook, Houston, Texas, United States

Olive Oil for High Risk Breast Cancer Prevention in Women

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Hydroxytyrosol

First Posted Date: 2014-02-21

Last Posted Date: 2023-10-10

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 51

Registration Number: NCT02068092

Locations: 🇺🇸
Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

Phase 1

Recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy

First Posted Date: 2013-07-31

Last Posted Date: 2016-07-01

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 25

Registration Number: NCT01913106

Locations: 🇺🇸
Houston Methodist, Houston, Texas, United States

Ciprofloxacin for Prevention of BK Infection

Phase 4

Completed

Conditions: BK Virus Infection

Interventions: Drug: placebo
Drug: Ciprofloxacin

First Posted Date: 2013-02-12

Last Posted Date: 2019-11-13

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 200

Registration Number: NCT01789203

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy